Your browser doesn't support javascript.
loading
Post-Authorization Safety Study of Hospitalization for Acute Kidney Injury in Patients with Type 2 Diabetes Exposed to Dapagliflozin in a Real-World Setting.
Johannes, Catherine B; Beachler, Daniel C; Layton, J Bradley; Danysh, Heather E; Ziemiecki, Ryan; Arana, Alejandro; Dinh, Jade; Li, Ling; Calingaert, Brian; Pladevall-Vila, Manel; Hunt, Phillip R; Chen, Hungta; Karlsson, Cecilia; Johnsson, Kristina; Gilsenan, Alicia.
Afiliação
  • Johannes CB; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, 307 Waverley Oaks Road, Suite 101, Waltham, MA, 02452, USA. cjohannes@rti.org.
  • Beachler DC; Department of Safety and Epidemiology, HealthCore, Inc., Wilmington, DE, USA.
  • Layton JB; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle Park, NC, USA.
  • Danysh HE; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, 307 Waverley Oaks Road, Suite 101, Waltham, MA, 02452, USA.
  • Ziemiecki R; Department of Biostatistics, RTI Health Solutions, Research Triangle Park, NC, USA.
  • Arana A; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, Barcelona, Spain.
  • Dinh J; Department of Safety and Epidemiology, HealthCore, Inc., Wilmington, DE, USA.
  • Li L; Department of Research Operations, HealthCore, Inc., Wilmington, DE, USA.
  • Calingaert B; Department of Safety and Epidemiology, HealthCore, Inc., Wilmington, DE, USA.
  • Pladevall-Vila M; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, Research Triangle Park, NC, USA.
  • Hunt PR; Department of Pharmacoepidemiology and Risk Management, RTI Health Solutions, Barcelona, Spain.
  • Chen H; The Center for Health Policy and Health Services Research, Henry Ford Health System, Detroit, MI, USA.
  • Karlsson C; BioPharmaceuticals Business Unit, AstraZeneca, Gaithersburg, MD, USA.
  • Johnsson K; BioPharmaceuticals Business Unit, AstraZeneca, Gaithersburg, MD, USA.
  • Gilsenan A; BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Drug Saf ; 46(2): 157-174, 2023 02.
Article em En | MEDLINE | ID: mdl-36528670
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Injúria Renal Aguda Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Injúria Renal Aguda Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans País/Região como assunto: America do norte Idioma: En Ano de publicação: 2023 Tipo de documento: Article